Bisni Narayanan, PharmD, MS

This milestone celebration not only honors CPA’s legacy but also underscores the profession’s future—one defined by collaboration, innovation, and a steadfast commitment to patient care.

With a better understanding of the underlying pathophysiology of chronic lymphocytic leukemia and the introduction of novel targeted agents, such as Bruton kinase Inhibitors, the prognosis of high-risk patients has changed dramatically.

Neuromyelitis optica spectrum disorder is an autoimmune disease characterized by severe attacks of optic neuritis and/or myelitis, leading to possible visual loss, paralysis, cognitive impairment, sensory deficits, bladder dysfunction, and even mortality.

With the advent of disease-modifying therapies, the life span of patients with multiple sclerosis has increased dramatically.

The goals of therapy for atopic dermatitis include reducing symptoms of pruritis and dermatitis with disease control and prevention of flares.

The FDA is evaluating the use of adagrasib (MRTX849) to treat patients with non-small cell lung cancer harboring a KRAS G12C mutation who have previously received at least 1 systemic therapy.

Poziotinib is an irreversible pan HER2 inhibitor with activity against mutations of HER1, HER2, and HER4.

The FDA approved decitabine/cedazuridine in 2020 for treatment of adults with myelodysplastic syndromes.